Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer

Outweighing the benefits and weakness of endoscopic submucosal dissection for early gastric cancer in the west

“…For the future, advances with high-throughput technology, genetics, genomics, genome-wide association studies, cancer genome, and computational network modeling allow us optimism for novel tailored biomarker-based prevention and treatment of patients with advanced cancer [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34]. …”

Anti-angiogenic therapies in prostate cancer

“…However, while the results of anti-angiogenic therapy in preclinical models have provided promising results, there is some discrepancy between these data and those obtained in CTs, and to date, there is no anti-angiogenic treatment approved by the FDA for the treatment of PCa. Anti-angiogenic treatments face several major challenges including intrinsic or acquired resistance, enhanced metastasis during treatment, relevant side-effects, and the lack of validated biomarkers for monitoring response to therapy that must be solved before introducing them into clinical practice [3,10,14,15]. As we continue to learn more about the angiogenesis process, therapies with new molecular targets will emerge, and together with the numerous ongoing and future CTs they will help to clarify the usefulness of antiangiogenic treatments in PCa.…”

Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management?

“…For example, inhibiting EGFR signaling pathway with the monoclonal antibodies cetuximab or panitumab only have therapeutic effects for KRAS wild-type metastatic colorectal cancer [11]. In the absence of molecular markers to select patients for anti-angiogenic therapy, such as bevacizumab, hope for effective treatment with anti-angiogenic agents without biomarker-based selection is minimal [12,13].…”